ClinicalTrials.gg
RecruitingNCT05797857Updated Nov 18, 2026

Exercise Training in Transthyretin Cardiac Amyloidosis

An interventional study of Exercise Training in Amyloid Cardiomyopathy and Transthyretin Cardiac Amyloidosis, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Amyloid Neuropathies, Familial with a site in United States — 23 open to participants now, 26 under way, 4 of them phase 3. Amyloid Neuropathies, Familial · United States.

Planned enrollment
24th of 38
40 · median 53
Started
2024
with 6 others
No phase
6 of 58
4 open now
Primary completion
2029-06
later than 18 of 25 live
Registered
38th of 58
by date
Lead sponsor
6 of 58
Brigham and Women's Hospital

Among the 58 studies in Amyloid Neuropathies, Familial with a site in United States, this one is the 24th largest by planned enrollment of the 38 interventional ones that give a count, is one of 7 that started in 2024, is one of 6 with no phase, reaches primary completion later than 18 of the 25 other live ones, and was the 38th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

23 of the 58 studies in Amyloid Neuropathies, Familial with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Amyloid Neuropathies, Familial with a site in United States, or all of them as a file.
02

Study summary

Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for transthyretin cardiac amyloidosis. This is a vital next step to improve functional capacity and quality of life of people suffering from transthyretin cardiac amyloidosis.

Read the detailed description

Heart failure (HF) affects over 5 million adults over the age of 65. Cardiac transthyretin amyloidosis (ATTR-CM) is a cause of HF in \~10% of older adults and leads to significant morbidity and mortality. Exercise intolerance is traditionally attributed to cardiac dysfunction but the contribution of other systems to this has not been studied. Musculoskeletal involvement is common in ATTR-CM and occur 5-10 years prior to onset of HF. Tafamidis, a transthyretin stabilizer, is the only approved treatment for ATTR-CM. It slows disease progression, prolongs life, and reduces HF hospitalizations. However, it does not improve functional capacity- no therapeutic intervention has been shown to do so in ATTR-CM.

The idea behind this project is that skeletal muscle dysfunction from amyloidosis and HF severely limits exercise capacity and, thus, quality of life in ATTR-CM, and that targeted exercise training will improve quality of life by improving skeletal muscle performance and aerobic capacity. Cardiopulmonary exercise testing (CPET) and the short physical performance battery (SBBP), including a leg extensor muscle power assessment will be used to achieve the following specific aims; 1) to compare skeletal muscle performance in ATTR-CM and non-amyloid HF; and 2) to determine improvements in aerobic capacity and quality of life due to 12 weeks of supervised exercise training in patients with ATTR-CM. To achieve the second aim, we will use a personalized exercise intervention.

03

Conditions studied

  • Amyloid Cardiomyopathy
  • Transthyretin Cardiac Amyloidosis
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis and typing of ATTR-CM by endomyocardial or by Grade 2 or Grade 3 pyrophosphate (PYP) positivity (exception: nonamyloid control arm in aim 1).

    • Diagnosis of heart failure, with prior or current need of diuretics and increased N-terminal prohormone B-natureitic peptide (BNP) (≥450 pg/ml).
    • Peak VO2 \<80% predicted, indicating impaired aerobic capacity (for aim 2 only).
    • Taking tafamidis (for aim 2 only)
    • Able to walk 4 meters (with or without the use of an assistive device) and independent with basic activities of daily living at the time of enrolment.
    • Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention.
    • Signed document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Acute myocardial infarction (Note: given that cardiac biomarkers such as troponin are frequently elevated in ATTR-CM patients, the diagnosis of acute myocardial infarction should be based on clinical diagnosis, not biomarkers alone)

    • >70% obstructive coronary artery disease
    • Severe aortic valve stenosis
    • Already actively participating in formal, facility-based cardiac exercise
    • Already engaging in regular moderate to vigorous exercise conditioning defined as > 30 minutes per day, ≥ twice per week consistently during the previous 6 weeks
    • Ventricular assist device
    • Light chain amyloidosis or other form of non-ATTR amyloidosis
    • Advanced chronic kidney disease defined as estimated \<20 mL/min/1.73m2
    • Any organ transplantation
    • Terminal illness other than HF with \< 1 year
    • Pacemaker or implantable cardioverter-defibrillato (ICD) with heart rate limits \< expected heart rates for exercise and unable to be reprogrammed
    • Neuropathy due to transthyretin (TTR) mutation
    • Impairment from stroke, injury or other medical disorder that precludes participation in the intervention
    • Abnormal cardiopulmonary exercise testing (CPET) finding that requires further investigation and management
    • Dementia that precludes ability to participate in exercise and follow study protocols
    • High risk for non-adherence as determined by screening evaluation
    • Inability or unwillingness to comply with the study requirements
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Other: Exercise Training

Interventions

  • OtherExercise Training

    A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.

06

What researchers measure

Primary outcomes

  1. peak oxygen consumption (VO2)

    CPET performed at baseline and 12-weeks, following the exercise intervention will be used to measure aerobic capacity, peak VO2. The change in peak VO2 from baseline to 12 weeks is the primary outcome measure. An increase of \> 1.0 ml/kg/min is considered a clinically meaningful increase

    Time frame: 12 weeks

Secondary outcomes

  1. Kansas City Cardiomyopathy Questionnaire

    Kansas City Cardiomyopathy Questionnaire (KCCQ) is a quality of life questionnaire. This will be recorded at baseline, 4-weeks and 12-weeks. The change in KCCQ score from baseline to 12 weeks is a secondary outcome. KCCQ scores are scaled from 0 to 100; where 0 denotes the lowest reportable health status and 100 the highest. An increase of 5 points is considered a clinically meaningful increase.

    Time frame: 12 weeks

  2. Lower extremity function

    The short physical performance battery (SPPB) is an assessment of lower extremity function. The change in SPPB score from baseline to 12 weeks is a secondary outcome. This is a scale of 0-12, where 0 denotes the worst performance and 12 the highest. An increase of 1 point is considered a clinically meaningful increase.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — A limited access dataset generated from this project will rapidly be made available to the broader community for distribution to outside researchers according to established Mass General Brigham and NHLBI procedures and in accordance with NIH policies. Exercise training plans developed as part of this proposal will be made available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2029, 59 months after the start.

Of 30 interventional studies with no phase under Amyloid Neuropathies, Familial, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 4, 2023
StartActual
Jul 10, 2024
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05797857
Responsible party
Sarah Cuddy, MD (Cardiologist, Brigham and Women's Hospital) — Principal investigator
First posted
Apr 4, 2023
Start date
Jul 10, 2024
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion